The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 08, 2022
Filed:
Jul. 26, 2016
Bebetter Med Inc., Guangdong, CN;
Xiong Cai, Guangdong, CN;
Changgeng Qian, Guangdong, CN;
Yunwo Weng, Guangdong, CN;
Bin Liu, Guangdong, CN;
Yanyan Wang, Guangdong, CN;
Mingsheng Lin, Guangdong, CN;
Junqi Li, Guangdong, CN;
Yuanhui Qing, Guangdong, CN;
Huajin You, Guangdong, CN;
Shiqing Zhou, Guangdong, CN;
Weicai Xue, Guangdong, CN;
BEBETTER MED INC., Guangdong, CN;
Abstract
Provided are a 2, 4-di-(nitrogen containing group) substituted pyrimidine compound represented by a general formula (I), a pharmaceutically acceptable salt and a stereoisomer thereof, a preparation method thereof, and a use thereof in preparation of anti-tumor drugs. The compound having a structural feature shown in the general formula (I) can selectively suppress activity of mutant epidermal growth factor receptors (EGFR), including single-mutant EGFR (T790M) and double-mutant EGFR (including L858R/T790M and ex19del/T790M), and can suppress activity of single gain-of-function mutant EGFR (including L858R and ex19del) as well. The compound has a weak suppression effect on wild-type EFGR and a very high selectivity, and thus it has a potential to be used in preparation of drugs for treating EGFR mutant tumors, especially non-small cell lung cancer (NSCLC) comprising a T790M EGFR mutation.